B

Bonus Biogroup Ltd
TASE:BONS

Watchlist Manager
Bonus Biogroup Ltd
TASE:BONS
Watchlist
Price: 9.9 ILS 1.02% Market Closed
Market Cap: 121.1m ILS
Have any thoughts about
Bonus Biogroup Ltd?
Write Note

Bonus Biogroup Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bonus Biogroup Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
B
Bonus Biogroup Ltd
TASE:BONS
Capital Expenditures
-â‚Ş464k
CAGR 3-Years
25%
CAGR 5-Years
-5%
CAGR 10-Years
8%
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Capital Expenditures
-$954k
CAGR 3-Years
-22%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Capital Expenditures
-$9.8m
CAGR 3-Years
-24%
CAGR 5-Years
-33%
CAGR 10-Years
-11%
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Capital Expenditures
-$95k
CAGR 3-Years
58%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Capital Expenditures
-$234k
CAGR 3-Years
32%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Capital Expenditures
-$7k
CAGR 3-Years
11%
CAGR 5-Years
29%
CAGR 10-Years
N/A
No Stocks Found

Bonus Biogroup Ltd
Glance View

Market Cap
121.1m ILS
Industry
Biotechnology

Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. The firm is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. The company is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.

BONS Intrinsic Value
0.41 ILS
Overvaluation 96%
Intrinsic Value
Price
B

See Also

What is Bonus Biogroup Ltd's Capital Expenditures?
Capital Expenditures
-464k ILS

Based on the financial report for Jun 30, 2024, Bonus Biogroup Ltd's Capital Expenditures amounts to -464k ILS.

What is Bonus Biogroup Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
8%

Over the last year, the Capital Expenditures growth was 70%. The average annual Capital Expenditures growth rates for Bonus Biogroup Ltd have been 25% over the past three years , -5% over the past five years , and 8% over the past ten years .

Back to Top